



TECHNICAL DATASHEET

## ETO polyclonal antibody

Other names: RUNX1T1, AML1T1, CBFA2T1, CDR, MTG8, ZMYND2

Cat. No. C15310001 Type: Polyclonal	<b>Specificity:</b> Human: positive Other species: not tested	
ChIP-grade / ChIP-seq-grade	<b>Purity:</b> Whole antiserum from rabbit containing 0.05% azide.	
Source: Rabbit	<b>Storage:</b> Store at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles.	
Lot #: A710-001		
<b>Size:</b> 100 µl	<b>Precautions:</b> This product is for research use only. Not for use in diagnostic or therapeutic procedures.	
Concentration: not determined		

**Description:** Polyclonal antibody raised in rabbit against human ETO (runt-related transcription factor 1; translocated to, 1 (cyclin D-related)) using two KLH-conjugated synthetic peptides containing sequences from the N-terminal and the central region of the protein, respectively.

## Applications

	Suggested dilution	Results
ChIP*	4 μl/ChIP	Fig 1, 2
ELISA	1:100	Fig 3

\* Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 µl per IP.

#### References citing this antibody:

 Martens JHA, Mandoli A, Simmer F, Wierenga B-J, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG (2012) ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 120: 4038-4048.

## Target description

ETO (UniProtKB/Swiss-Prot entry Q06455) is a transcriptional regulator which belongs to the myeloid translocation gene family. ETO exerts its function by interaction with transcription factors bound to promoters and binding to histone deacetylases. It recruits a range of corepressors to facilitate transcriptional repression. The t(8;21)(q22;q22) translocation is one of the most frequent karyotypic abnormalities in acute myeloid leukaemia. This translocation produces a chimeric gene made up of the 5'-region of AML1and the 3'-region of the ETO gene. The chimeric protein is thought to associate with the nuclear corepressor/ histone deacetylase complex to block hematopoietic differentiation.

#### Results



# Figure 1. ChIP results obtained with the Diagenode antibody directed against ETO

ChIP assays were performed using SKNO-1 cells, the Diagenode antibody against ETO (Cat. No. C15310001) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4  $\mu$ l of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2, OGG1 and VEGF genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the H2B gene was used.



B. Genomic region on chromosome 3 surrounding the OGG1 gene



Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against ETO

ChIP was performed as described above. The IP'd DNA of 6 ChIP's was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer's instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.



#### Figure 3. Determination of the antibody titer

To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against human ETO (Cat. No. C15310001). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:1,300.

#### Diagenode sa. BELGIUM | EUROPE

LIEGE SCIENCE PARK Rue Bois Saint-Jean, 3 4102 Seraing (Ougrée) - Belgium Tel: +32 4 364 20 50 Fax: +32 4 364 20 51 orders@diagenode.com info@diagenode.com

#### Diagenode Inc. USA | NORTH AMERICA

400 Morris Avenue, Suite 101 Denville, NJ 07834 - USA Tel: +1 862 209-4680 Fax: +1 862 209-4681 orders.na@diagenode.com info.na@diagenode.com Last update: August 31, 2012